Improved Hypoxic Microenvironment By Nanoformulation For Effective T Cell Therapy In Mice Model.

Area of Science:

• Biomedical Engineering
• Immunology
• Materials Science

Background:

• Adoptive cell therapy (ACT) shows promise for cancer treatment but is limited by the immunosuppressive tumor microenvironment (TME) in solid tumors.
• Hypoxia within the TME hinders immune cell function and reduces ACT efficacy.
• Developing strategies to overcome TME-induced immunosuppression is crucial for enhancing ACT outcomes.

Purpose of the Study:

• To develop a tumor microenvironment-responsive nanoplatform for co-delivery of immunostimulants and oxygen-generating agents.
• To enhance dendritic cell (DC)-mediated antitumor immunity and improve ACT efficacy in solid tumors.
• To investigate the potential of this nanoplatform in alleviating tumor hypoxia and remodeling the immunosuppressive TME.

Main Methods:

• Mesoporous silica nanospheres (MSNs) were formulated co-loaded with imiquimod (R837), zinc peroxide (ZnO2), and manganese peroxide (MnO2).
• In vitro studies involved DC activation assays.
• In vivo efficacy was evaluated in an H22 murine hepatocellular carcinoma model using flow cytometry and immunofluorescence microscopy to assess immune cell infiltration and tumor hypoxia.

Main Results:

• The developed MSN formulation effectively alleviated intratumoral hypoxia by generating oxygen.
• The nanoplatform promoted DC maturation (CD80+CD86+) and enhanced effector CD8+ T cell infiltration into tumors.
• Co-administration of the nanoformulation with ACT resulted in significant tumor suppression and systemic antitumor immune responses with no observed organ toxicity.

Conclusions:

• The oxygen-producing immunomodulatory nanoplatform successfully remodels the immunosuppressive TME.
• This strategy significantly enhances the efficacy of ACT in solid tumors.
• The developed nanoplatform offers a promising therapeutic approach to overcome current limitations in T cell-based immunotherapy for solid tumors.